CanBas Co., Ltd.

Research CanBas Co., Ltd. (4575.T) on Bullrun: market cap JPY 15.41B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker4575.T
ExchangeTSE
CountryJapan
SectorHealthcare
IndustryBiotechnology
CurrencyJPY
Market capJPY 15.41B
Financial periodFY2025

Valuation Snapshot

latest market cap is JPY 15.41B.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	n/a	n/a	n/a	n/a	-61.14	n/a	n/a	n/a
FY2024	JPY 0	-JPY 1.21B	-JPY 1.28B	n/a	-67.9	JPY 1.89B	n/a	JPY 2.34B
FY2023	JPY 0	-JPY 1.24B	-JPY 1.40B	n/a	-83.03	JPY 1.62B	JPY 0	JPY 1.93B
FY2022	JPY 0	-JPY 855.58M	-JPY 719.81M	n/a	-88.31	JPY 737.78M	JPY 367.34M	JPY 250.69M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	JPY 15.41B	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 JPY.

About CanBas Co., Ltd.

CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. The company develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

Related stock research

Japan stocks Japan Healthcare stocks A-Z stock index

Other Healthcare stocks

Veritas In Silico Inc. (130A.T) Kohjin Bio Co., Ltd. (177A.T) Chordia Therapeutics Inc. (190A.T) PRISM BioLab Co.,LTD (206A.T) GNI Group Ltd. (2160.T) Linical Co., Ltd. (2183.T) Heartseed Inc. (219A.T) Transgenic Group Inc. (2342.T) Soiken Holdings Inc. (2385.T) ADR Biomedical Holdings Inc. (3750.T) AnGes, Inc. (4563.T) OncoTherapy Science, Inc. (4564.T)

Frequently asked questions

What is CanBas Co., Ltd.'s market cap?

CanBas Co., Ltd.'s market capitalization is JPY 15.41B.